专利检索 ap:("Merck Sharp & Dohme Corp.") AND inv:"ZARTMAN, Blair, C." 第 1 页

1.

发明授权
N-Piperidinone-indane carboxamides as CGRP receptor antagonists 有权
标题翻译：的N-哌啶酮 - 茚满甲酰胺，为CGRP受体拮抗剂

公开(公告)号：EP2637656B1

公开(公告)日：2016-12-14

申请号：EP11840630.5

申请日：2011-11-10

申请人： Merck Sharp & Dohme Corp.

发明人： BELL, Ian, M. , FRALEY, Mark, E. , GALLICCHIO, Steven, N. , GINNETTI, Anthony , MITCHELL, Helen, J. , PAONE, Daniel, V. , STAAS, Donnette, D. , WANG, Cheng , ZARTMAN, Blair, C. , STEVENSON, Heather, E.

IPC分类号： C07D471/04 , C07D487/04 , A61K31/40 , A61K31/445 , A61K31/506

CPC分类号： C07D471/04 , A61K31/506 , C07D487/04

2.

发明授权
CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS 有权
标题翻译：甲螺乙内酰脲CGRP受体拮抗剂

公开(公告)号：EP1613368B1

公开(公告)日：2011-11-30

申请号：EP04719234.9

申请日：2004-03-10

申请人： Merck Sharp & Dohme Corp.

发明人： BELL, Ian, M. , GALLICCHIO, Steven, N. , STUMP, Craig, A. , ZARTMAN, Blair, C.

IPC分类号： C07D235/02 , C07D233/02 , A61K31/415 , A61P25/06

CPC分类号： C07D233/78 , C07D235/02 , C07D401/12 , C07D403/12 , C07D413/12 , C07D471/10 , C07D513/04

摘要： The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

3.

发明公开
PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS 有权
标题翻译：的N-哌啶酮 - 茚满甲酰胺，为CGRP受体拮抗剂

公开(公告)号：EP2637656A1

公开(公告)日：2013-09-18

申请号：EP11840630.5

申请日：2011-11-10

申请人： Merck Sharp & Dohme Corp.

发明人： BELL, Ian, M. , FRALEY, Mark, E. , GALLICCHIO, Steven, N. , GINNETTI, Anthony , MITCHELL, Helen, J. , PAONE, Daniel, V. , STAAS, Donnette, D. , WANG, Cheng , ZARTMAN, Blair, C. , STEVENSON, Heather, E.

IPC分类号： A61K31/40 , A61K31/445

CPC分类号： C07D471/04 , A61K31/506 , C07D487/04

摘要： The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.